Italian Drug Maker Menarini Aims To Expand Into US and Japan
The corporate licensing director at A. Menarini IFR tells Sten Stovall why and how Italy's largest drug maker plans to expand into the US and Japanese markets.
You may also be interested in...
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.